[{"orgOrder":0,"company":"Qassim Health Cluster","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"SAUDI ARABIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Articaine Hydrochloride","moa":"Sodium channel alpha subunit","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Qassim Health Cluster","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qassim Health Cluster \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Qassim Health Cluster \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Articaine Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Qassim Health Cluster

                          Country arrow
                          PREP
                          Not Confirmed

                          Qassim Health Cluster

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Articaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dental Caries.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 03, 2023

                          Lead Product(s) : Articaine Hydrochloride

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Michigan

                          Country arrow
                          PREP
                          Not Confirmed

                          University of Michigan

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Articaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulpitis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 21, 2011

                          Lead Product(s) : Articaine Hydrochloride

                          Therapeutic Area : Dental and Oral Health

                          Highest Development Status : Phase IV

                          Sponsor : Dentsply International

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank